Tiotropium
- Generic Name
- Tiotropium
- Brand Names
- Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto
- Drug Type
- Small Molecule
- Chemical Formula
- C19H22NO4S2
- CAS Number
- 186691-13-4
- Unique Ingredient Identifier
- 0EB439235F
- Background
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than ipratropium.
Tiotropium was granted FDA approval on 30 January 2004.
- Indication
Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old. A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD
Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03258749
- Locations
- 🇨🇳
Huashan hospital,Fudan university, Shanghai, Shanghai, China
Two-period 21 Day Cross-over Study to Compare the Pharmacokinetics of Tiotropium From Two Inhalers
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Solventum US LLC
- Target Recruit Count
- 40
- Registration Number
- NCT03246581
- Locations
- 🇬🇧
3M Health Care, Loughborough, United Kingdom
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 302
- Registration Number
- NCT03240575
- Locations
- 🇺🇸
Pulmonary Rsrch Inst of SE MI, Farmington Hills, Michigan, United States
🇺🇸Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- COPD ExacerbationCOPD
- Interventions
- Device: Dry Powder InhalerDevice: Nebulizers
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT03219866
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
Efficacy of Intermittent Tiotropium in Early Childhood Wheezing
- Conditions
- WheezingObstruction AirwayWheezy BronchitisAsthmatic Bronchitis
- Interventions
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03199976
- Locations
- 🇫🇮
Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland
Specific Use-Result of Spiriva Respimat® in Asthmatics
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 193
- Registration Number
- NCT03188120
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1426
- Registration Number
- NCT03158311
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Solventum US LLC
- Target Recruit Count
- 46
- Registration Number
- NCT03155204
- Locations
- 🇬🇧
3M Health Care, Loughborough, United Kingdom
INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 80
- Registration Number
- NCT03152149
- Locations
- 🇬🇧
NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
🇬🇧NHS Tayside, Dundee, United Kingdom
🇬🇧Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: GSP304 Placebo Inhalation SolutionDrug: GSP304 (tiotropium bromide) Inhalation Solution
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Glenmark Specialty S.A.
- Target Recruit Count
- 155
- Registration Number
- NCT03118765
- Locations
- 🇺🇸
Glenmark Investigational Site 13, Winter Park, Florida, United States
🇺🇸Glenmark Investigational Site 22, Columbus, Ohio, United States
🇺🇸Glenmark Investigational Site 3, Easley, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.